Tuesday, April 05, 2022 6:51:01 PM
Enzolytics, a Texas-based maker of monoclonal antibody drugs, has inked a deal with Samsung Biologics to support and manufacture its investigational new drug treatments for HIV and COVID-19.
Samsung Biologics will produce a stable cell line and other materials for Enzolytics' monoclonal antibodies from facilities in San Francisco and Incheon, South Korea. (Samsung Biologics)
October 7, 2021
https://www.fiercepharma.com/manufacturing/enzolytics-inks-cmo-deal-samsung-for-covid-19-hiv-drugs
Recent ENZC News
- Small Cap Recipient of Military Drone Technology • InvestorsHub NewsWire • 11/20/2023 01:14:45 PM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM